prikaz prve stranice dokumenta A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
  Download
PDF 3.43 MB
Scientific paper - Original scientific paper
A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
Pharmaceutics, 13 (2021), 6; 795. https://doi.org/10.3390/pharmaceutics13060795
Nižić Nodilo, Laura; Ugrina, Ivo; Špoljarić, Drago; Amidžić Klarić, Daniela; Jakobušić Brala, Cvijeta; Perkušić, Mirna; Pepić, Ivan; Lovrić, Jasmina; Saršon, Vesna; Safundžić Kučuk, Maša; Zadravec, Dijana; Kalogjera, Livije; Hafner, Anita

Cite this document

Nižić Nodilo, L., Ugrina, I., Špoljarić, D., Amidžić Klarić, D., Jakobušić Brala, C., Perkušić, M. ... Hafner, A. (2021). A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies. Pharmaceutics, 13. (6). doi: 10.3390/pharmaceutics13060795

Nižić Nodilo, Laura, et al. "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies." Pharmaceutics, vol. 13, no. 6, 2021. https://doi.org/10.3390/pharmaceutics13060795

Nižić Nodilo, Laura, Ivo Ugrina, Drago Špoljarić, Daniela Amidžić Klarić, Cvijeta Jakobušić Brala, Mirna Perkušić, Ivan Pepić, et al. "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies." Pharmaceutics 13, no. 6 (2021). https://doi.org/10.3390/pharmaceutics13060795

Nižić Nodilo, L., et al. (2021) 'A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies', Pharmaceutics, 13(6). doi: 10.3390/pharmaceutics13060795

Nižić Nodilo L, Ugrina I, Špoljarić D, Amidžić Klarić D, Jakobušić Brala C, Perkušić M, and sur.. A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies. Pharmaceutics [Internet]. 2021 May 26 [cited 2024 October 29];13(6). doi: 10.3390/pharmaceutics13060795

L. Nižić Nodilo, et al., "A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies", Pharmaceutics, vol. 13, no. 6, May 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:605462. [Accessed: 29 October 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies
AuthorLaura Nižić Nodilo
AuthorIvo Ugrina
AuthorDrago Špoljarić
AuthorDaniela Amidžić Klarić
AuthorCvijeta Jakobušić Brala
AuthorMirna Perkušić
AuthorIvan Pepić
AuthorJasmina Lovrić
AuthorVesna Saršon
AuthorMaša Safundžić Kučuk
AuthorDijana Zadravec
AuthorLivije Kalogjera
AuthorAnita Hafner
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Othorhinolaryngology and Head and Neck Surgery)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Otorhinolaryngology
Abstract (english)
Nasal route of administration offers a unique opportunity of brain targeted drug delivery via olfactory and trigeminal pathway, providing effective CNS concentrations at lower doses and lower risk for adverse reactions compared to systemic drug administration. Therefore, it has been recently proposed as a route of choice for glucocorticoids to control neuroinflammation processes in patients with severe Covid-19. However, appropriate delivery systems tailored to enhance their efficacy yet need to emerge. In this work we present the development of sprayable brain targeting powder delivery platform of dexamethasone sodium phosphate (DSP). DSP-loaded microspheres, optimised employing Quality-by-Design approach, were blended with soluble inert carriers (mannitol or lactose monohydrate). Powder blends were characterized in terms of homogeneity, flow properties, sprayability, in vitro biocompatibility, permeability and mucoadhesion. Nasal deposition studies were performed using 3D printed nasal cavity model. Mannitol provided better powder blend flow properties compared to lactose. Microspheres blended with mannitol retained or enlarged their mucoadhesive properties and enhanced DSP permeability across epithelial model barrier. DSP dose fraction deposited in the olfactory region reached 17.0% revealing the potential of developed powder platform for targeted olfactory delivery. The observed impact of nasal cavity asymmetry highlighted the importance of individual approach when aiming olfactory region.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePharmaceutics
Numberingvol. 13, no. 6, 795
e-ISSN1999-4923
DOIhttps://doi.org/10.3390/pharmaceutics13060795
URN:NBNurn:nbn:hr:105:605462
Publication2021-05-26
ProjectNumber: UIP-2017-05-4592
Title (croatian): Optimiranje depozicije raspršenih in situ gelirajućih i praškastih terapijskih sustava u nosnoj šupljini
Acronym: OptiNasalSpray
Leader: Anita Hafner
Jurisdiction: Croatia
Funding stream: UIP
Document URLhttps://www.mdpi.com/1999-4923/13/6/795
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-12-16 10:08:34